Statement of Changes in Beneficial Ownership (4)
October 18 2021 - 06:21PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
KWON YOUNG |
2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC.
[
ADMA
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O ADMA BIOLOGICS, INC., 465 STATE ROUTE 17 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
10/15/2021 |
(Street)
RAMSEY, NJ 07446
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (right to buy) | $1.1 | 10/15/2021 | | A | | 93500 | | (1) | 10/15/2031 | Common Stock | 93500 | $0 | 93500 | D | |
Explanation of Responses: |
(1) | Reflects the grant of a stock option to purchase 93,500 shares of common stock, $0.0001 par value per share ("Common Stock") of ADMA Biologics, Inc. The shares of Common Stock underlying the stock option will vest in 12 equal monthly installments, becoming fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service on the applicable vesting date. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
KWON YOUNG C/O ADMA BIOLOGICS, INC. 465 STATE ROUTE 17 RAMSEY, NJ 07446 | X |
|
|
|
Signatures
|
/s/ Young T. Kwon, by Brian Lenz as attorney-in-fact | | 10/18/2021 |
**Signature of Reporting Person | Date |
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Mar 2023 to Mar 2024